Moderna, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Moderna, Inc. (MRNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $19.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-20
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-12-31 was $400.00M, a 13.93% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-09-30 was $625.00M, a 380.77% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-06-30 was $325.00M, a 31.63% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-03-31 was $250.00M, a 331.03% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $19.00M, a 84.43% decline from fiscal 2024.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $122.00M, a 70.46% decline from fiscal 2023.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $413.00M, a 42.16% decline from fiscal 2022.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $714.00M, a 55.38% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $19.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $122.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $413.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $714.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $400.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $1.02B derived: sum of 2 quarters · filed 2024-02-23 | $1.35B derived: sum of 3 quarters · filed 2024-02-23 | $1.60B 10-K · filed 2024-02-23 | |
| 2021-09-30 | $625.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $950.00M derived: sum of 2 quarters · filed 2021-11-04 | $1.20B 10-Q · filed 2021-11-04 | $1.55B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | $325.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $575.00M 10-Q · filed 2021-08-05 | $926.10M derived: sum of 3 quarters · filed 2023-02-24 | $1.06B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | $250.00M 10-Q · filed 2021-05-06 | $601.10M derived: sum of 2 quarters · filed 2023-02-24 | $731.10M derived: sum of 3 quarters · filed 2023-02-24 | $978.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $351.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $481.10M derived: sum of 2 quarters · filed 2023-02-24 | $728.00M derived: sum of 3 quarters · filed 2023-02-24 | $786.00M 10-K · filed 2023-02-24 | $785.70M 10-K · filed 2021-02-26 |
| 2020-09-30 | $130.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $376.90M derived: sum of 2 quarters · filed 2020-10-30 | $434.90M 10-Q · filed 2020-10-30 | $471.80M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $246.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $304.90M 10-Q · filed 2020-08-06 | $341.80M derived: sum of 3 quarters · filed 2022-02-25 | $366.10M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | $58.00M 10-Q · filed 2020-05-07 | $94.90M derived: sum of 2 quarters · filed 2022-02-25 | $119.20M derived: sum of 3 quarters · filed 2022-02-25 | $133.90M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $36.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $61.20M derived: sum of 2 quarters · filed 2022-02-25 | $75.90M derived: sum of 3 quarters · filed 2022-02-25 | $76.00M 10-K · filed 2022-02-25 | $75.60M 10-K · filed 2020-02-27 |
| 2019-09-30 | $24.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $39.00M derived: sum of 2 quarters · filed 2019-11-06 | $39.10M 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $14.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $14.80M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $100.00K 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $5.30M 10-K · filed 2021-02-26 | ||||
| 2017-12-31 | $100.00K 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $200.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |